The PR Crime That Stayed Solved

The Tylenol Murders, Johnson & Johnson, and how a crisis management playbook became the official story.

The story you know goes like this.

In the fall of 1982, a random killer — still unidentified — purchased Tylenol bottles from Chicago-area stores, laced the capsules with cyanide, and returned them to the shelves. Seven people died before anyone knew what was happening. Johnson & Johnson responded with extraordinary speed and moral clarity: they recalled 31 million bottles, cooperated fully with authorities, and redesigned their packaging to prevent future tampering. The PR playbook was born. Crisis management was transformed. And though the killer was never caught, J&J emerged with its reputation not just intact but enhanced.

That version of events is taught at Harvard Business School. It has been the subject of books, case studies, and decades of admiring coverage. J&J chairman James Burke was celebrated as a model of corporate leadership under pressure. Harold Burson, the PR executive credited with managing the response, became a legend in his field.

The narrative is so complete, so polished, so thoroughly institutionalized, that the questions it forecloses have been almost entirely invisible for forty years.

What did J&J know before the deaths? What happened to the evidence a company attorney may have compromised on the morning of October 1, 1982? Why did J&J sell tamper-evident packaging to hospitals but not to the consumers who died? Why did the lawsuits settle confidentially, on the eve of trial, after discovery produced nearly 300 prior complaints? And why has the company that controlled the crime scene narrative from the first hours of the investigation never had to answer those questions publicly?

The mystery of who killed seven people in Chicago in 1982 has never been solved. The mystery of what Johnson & Johnson knew, and when, and what they did about it — that one has been papered over with a PR triumph so effective that questioning it still feels almost impolite.

Rita ruins it anyway.

The standard account of J&J’s response emphasizes speed, transparency, and consumer protection. The recall of 31 million bottles is presented as a selfless act — a company choosing public safety over profit. The narrative is not wrong exactly. The recall was real. The new packaging was real. The cooperation with law enforcement, at a surface level, was real.

What the standard account leaves out is the other layer of the institutional response: the layer that was less about transparency and more about control.

The Attorney and the Evidence

On the morning of October 1, 1982 — less than 48 hours after the first deaths — a Johnson & Johnson attorney appeared at the Elmhurst Police Department. According to a police report cited in subsequent Chicago Tribune reporting, the attorney said he had been conducting his own investigation into the death of Mary McFarland, one of the seven victims.

The detective who encountered him noted something troubling in the official report: he expressed concern that the attorney may have been destroying fingerprints or other valuable evidence during the course of his private investigation. That concern is in the police record. It was noted. And then, as far as the public record shows, it went nowhere.

The Hospital Packaging Problem

In 1982, Johnson & Johnson sold Tylenol to hospitals in tamper-evident packaging. The institutional customer received a product with safeguards against tampering. The consumer walking into a Walgreens or a Jewel Foods did not.

This is not a minor detail. It means J&J understood, before the deaths, that tamper-evident packaging was both technically feasible and operationally available. They had designed it. They were using it. They had simply not applied it to their largest consumer market.

“It should have alerted McNeil and Johnson & Johnson that any form of tampering was possible.” — Attorney Michael Demetrio, representing the Kellerman and McFarland families, Chicago Tribune

The 300 Prior Complaints

During civil discovery, J&J turned over documentation showing that it had received nearly 300 consumer complaints involving tampering, mix-ups, or contamination before the murders. Three hundred complaints. Before seven people died.

The civil case settled confidentially in 1991, on the eve of trial. The full evidentiary record — including whatever those 300 complaints showed about what J&J knew and when — was sealed behind a nondisclosure agreement. The public never learned what was in those complaints. The families could not speak about what they had learned. And the PR narrative, undisturbed by trial testimony or public disclosure, continued its march through the business school curricula of America.

Rita Ruins Everything does not speculate beyond the record. So here is what the record actually supports, as distinct from what has been alleged, theorized, or dramatized.

The standard narrative resolves the gap by treating the external tampering theory as settled fact, the recall as proof of good faith, and the confidential settlement as a private matter. What that resolution requires is ignoring the 300 prior complaints, the hospital packaging disparity, the detective’s documented concern, and the question of what might have come out at trial.

The evidence does not require us to conclude that J&J was responsible for the deaths. It does require us to conclude that the version of this story in which J&J is purely a victim — heroic, transparent, wronged by a random criminal — cannot survive contact with the documentary record.

When Corporate Crisis Management Controls the Crime Scene

From the first hours of the investigation, J&J had a structural advantage that no criminal defendant would ever be permitted: it was simultaneously a cooperating party in the investigation and an entity with significant interest in how the investigation’s narrative developed. J&J established direct relationships with the Chicago Police Department, the FBI, and the FDA in the immediate aftermath of the deaths. This is presented in the standard account as evidence of transparency. It is also a description of a company that was in the room where the investigative framing happened.

The Confidential Settlement and What It Buried

In 1991, nine years after the deaths and on the eve of trial, the civil lawsuits settled confidentially. The terms were never disclosed. The families could not discuss what they had learned through discovery. A trial would have been public. Testimony would have been public. The evidentiary record would have been public. The settlement ensured none of that happened. The families received compensation. The public received the continued absence of answers.

The coverage of the Tylenol murders in 1982 was, by any measure, extraordinary. The case generated national panic, transformed Halloween candy safety concerns for a generation, and reshaped the entire over-the-counter pharmaceutical industry. It deserved the coverage it got.

What the coverage did not do, at any significant scale, was interrogate J&J’s pre-crisis knowledge. The 300 complaints did not become a major story in 1982. The hospital packaging disparity did not generate sustained investigative attention. The detective’s documented concern about evidence compromise was not a prominent thread in the reporting.

Instead, the media narrative converged on two tracks: the search for the unknown killer and the celebration of J&J’s response. Both served journalistic needs. Neither required reporting on what J&J knew before people died. The PR playbook itself became the story.

Mary Kellerman was 12 years old. She had a cold.

Adam Janus was 27. His brother Stanley, 25, and sister-in-law Theresa, 19, came to mourn him and found the same bottle. Mary McFarland was 31. Mary Reiner was 27, a mother of four. Paula Prince was 35.

Seven people. None of them had any reason to believe that a product marketed as medicine, purchased from a legitimate retail store, could kill them. The regulatory framework that was supposed to protect them had a gap. The company that manufactured the product had received nearly 300 complaints about tampering and contamination. The packaging that protected hospital patients had not been extended to retail consumers.

The families received confidential settlements in 1991. What they received has never been disclosed. What they did not receive is a public accounting of what J&J knew before their family members died, a trial at which that question could have been examined, or a criminal conviction of anyone responsible for the deaths.

The case is still cold. Johnson & Johnson is ranked among the world’s most respected companies. The crisis management playbook that protected that reputation is taught as a model of ethical corporate leadership. The gap between those two sentences is not rhetorical. It is the actual, documented distance between what the families got and what the company got from the same set of events.